Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is -14.37% lower on its value in year-to-date trading and has touched a low of $4.71 and a high of $10.67 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AUPH stock was last observed hovering at around $7.55 in the last trading session, with the day’s gains setting it 0.14%.
Currently trading at $7.69, the stock is -11.82% and -11.08% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.14 million and changing 1.85% at the moment leaves the stock 16.13% off its SMA200. AUPH registered -0.65% loss for a year compared to 6-month gain of 32.59%. The firm has a 50-day simple moving average (SMA 50) of $8.6384 and a 200-day simple moving average (SMA200) of $6.6085.
The stock witnessed a -20.64% loss in the last 1 month and extending the period to 3 months gives it a 8.01%, and is -8.67% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.41% over the week and 3.91% over the month.
Aurinia Pharmaceuticals Inc (AUPH) has around 300 employees, a market worth around $1.10B and $220.36M in sales. Fwd P/E is 13.44. Profit margin for the company is -10.23%. Distance from 52-week low is 63.27% and -27.93% from its 52-week high. The company has generated returns on investments over the last 12 months (-4.90%).
with sales reaching $59.94M over the same period.The EPS is expected to grow by 104.81% this year, but quarterly earnings will post 34.20% year-over-year. Quarterly sales are estimated to grow 32.93% in year-over-year returns.
258.0 institutions hold shares in Aurinia Pharmaceuticals Inc (AUPH), with institutional investors hold 45.48% of the company’s shares. The shares outstanding are 143.11M, and float is at 128.78M with Short Float at 4.50%. Institutions hold 42.20% of the Float.
The top institutional shareholder in the company is ARMISTICE CAPITAL, LLC with over 11.14 million shares valued at $63.59 million. The investor’s holdings represent 7.7326 of the AUPH Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 9.27 million shares valued at $52.94 million to account for 6.4384 of the shares outstanding. The other top investors are NEA MANAGEMENT COMPANY, LLC which holds 3.97 million shares representing 2.7566 and valued at over $22.67 million, while STATE STREET CORP holds 1.9999 of the shares totaling 2.88 million with a market value of $16.45 million.
Aurinia Pharmaceuticals Inc (AUPH) Insider Activity
The most recent transaction is an insider purchase by TANG KEVIN, the company’s Director. SEC filings show that TANG KEVIN bought 500,000 shares of the company’s common stock on Dec 09 ’24 at a price of $9.09 per share for a total of $4.54 million. Following the purchase, the insider now owns 8.43 million shares.
Aurinia Pharmaceuticals Inc disclosed in a document filed with the SEC on Dec 06 ’24 that TANG KEVIN (Director) bought a total of 400,000 shares of the company’s common stock. The trade occurred on Dec 06 ’24 and was made at $9.01 per share for $3.6 million. Following the transaction, the insider now directly holds 7.93 million shares of the AUPH stock.
Still, SEC filings show that on Dec 05 ’24, TANG KEVIN (Director) acquired 300,000 shares at an average price of $8.91 for $2.67 million. The insider now directly holds 7,529,500 shares of Aurinia Pharmaceuticals Inc (AUPH).
